Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) insider John T. Curnutte sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 18th. The stock was sold at an average price of $65.00, for a total transaction of $650,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
John T. Curnutte also recently made the following trade(s):
- On Monday, June 26th, John T. Curnutte sold 60,000 shares of Portola Pharmaceuticals stock. The stock was sold at an average price of $57.88, for a total transaction of $3,472,800.00.
Portola Pharmaceuticals, Inc. (NASDAQ PTLA) traded down 1.60% on Tuesday, reaching $60.71. 512,527 shares of the company’s stock traded hands. Portola Pharmaceuticals, Inc. has a 12 month low of $15.68 and a 12 month high of $67.10. The company’s market cap is $3.46 billion. The firm’s 50 day moving average price is $54.88 and its 200 day moving average price is $40.51.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.46. The business had revenue of $5.12 million for the quarter, compared to analysts’ expectations of $4.21 million. Portola Pharmaceuticals had a negative net margin of 759.21% and a negative return on equity of 106.68%. The firm’s revenue for the quarter was down 37.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.15) earnings per share. On average, equities analysts expect that Portola Pharmaceuticals, Inc. will post ($4.29) EPS for the current fiscal year.
A number of research analysts have recently issued reports on PTLA shares. ValuEngine upgraded shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Citigroup Inc. set a $51.00 price target on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, April 12th. BidaskClub upgraded shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Zacks Investment Research upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $70.00 target price on the stock in a research report on Tuesday, July 18th. Finally, Credit Suisse Group reiterated a “neutral” rating and set a $58.00 target price (up previously from $39.00) on shares of Portola Pharmaceuticals in a research report on Monday, June 26th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $62.27.
A number of hedge funds have recently added to or reduced their stakes in PTLA. IFP Advisors Inc boosted its stake in Portola Pharmaceuticals by 7.7% in the second quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 170 shares during the period. First Mercantile Trust Co. bought a new stake in Portola Pharmaceuticals during the first quarter valued at $165,000. Ameritas Investment Partners Inc. purchased a new position in shares of Portola Pharmaceuticals during the first quarter valued at approximately $167,000. Fortaleza Asset Management Inc. purchased a new position in shares of Portola Pharmaceuticals during the first quarter valued at approximately $193,000. Finally, Credit Agricole S A purchased a new position in shares of Portola Pharmaceuticals during the first quarter valued at approximately $196,000. Institutional investors and hedge funds own 84.95% of the company’s stock.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
